Rayno Life Science Stocks: ALXN, BIIB, GILD, REGN, RHHBY Update 1

Update 12:40p  NASDAQ Up 2%

Cardiovascular Sciences follow url (CSII $33.90) Up 15 %Beats on Revenues and EPS. Q2 Revenues up 28% to $32.3M. Net Loss was $8.7M compared to $5.8M in 2013 fiscal Q2.

Thermo Fisher buy provigil online uk (TMO $114) up 2.4% on 10% 2013 EPS gain. Q4 revenues up 6% to $3.47B.

All Rayno stocks are green today except Nanosphere (NSPH) and Qiagen (QGEN).

buy priligy 60mg uk Biotech Rally Resumes With Large Caps-IBB up 3.2%

Alexion (ALXN $155) soars 15% on Q4 and Full Year Results

Product sales increased 37% to $1.55B, GAAP Net Income was $252.9M or $1.27/sh. Guides above consensus. The stock was added to the Rayno Portfolio on 2/2/09 at a price of $35.

Biogen (BIIB $313) back up 2.4%on 2013 Earnings, Conservative guidance.

Gilead (GILD) and Regeneron (REGN) stocks also up about 2%.

Vertex (VRTX $83.50) up 5.94% on disappointing guidance? 2013 Revenues of $1.21 B. 2013 GAAP loss of $445M. Incivek HCV sales were down.We added VRTX in November at a price of $63.However Q$ was profitable because of a royalty deal in Europe on Incivek. Guidance for revenue for 2014 is $570M-600M.

Adding Roche Holding (RHHBY $67) to Rayno Portfolio based on J.P.Morgan Presentation. Largest pure play in biopharma and diagnostics.

, , ,

No comments yet.

Leave a Reply